Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.

NCT05760378 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

223

Enrollment

OTHER

Sponsor class

Conditions

Triple-Negative Breast Cancer

Interventions

DRUG: Famitinib
DRUG: Camrelizumab
DRUG: nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin

Sponsor

Fudan University